Linked Life Data

12480701

Source:http://linkedlifedata.com/resource/pubmed/id/12480701

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2003-4-3
pubmed:abstractText
Antithrombin (AT) supplementation in patients with severe sepsis has been shown to improve organ failures in which activated leukocytes are critically involved. However, the precise mechanism(s) for the therapeutic effects of AT is not well understood. We examined in rats whether AT reduces ischemia/reperfusion (I/R)-induced renal injury by inhibiting leukocyte activation. AT markedly reduced the I/R-induced renal dysfunction and histologic changes, whereas neither dansyl glutamylglycylarginyl chloromethyl ketone-treated factor Xa (DEGR-F.Xa), a selective inhibitor of thrombin generation, nor Trp49-modified AT, which lacks affinity for heparin, had any effect. Renal tissue levels of 6-keto-PGF(1 alpha), a stable metabolite of prostacyclin (PGI(2)), increased after renal I/R. AT enhanced the I/R-induced increases in renal tissue levels of 6-keto-PGF(1 alpha), whereas neither DEGR-F.Xa nor Trp49-modified AT had any effect. AT significantly inhibited I/R-induced decrease in renal tissue blood flow and the increase in the vascular permeability. Ischemia/reperfusion-induced increases in renal tissue levels of tumor necrosis factor-alpha, cytokine-induced neutrophil chemoattractant, and myeloperoxidase were significantly inhibited in animals given AT. Pretreatment of animals with indomethacin reversed the effects induced by AT. Iloprost, an analog of PGI(2), produced effects similar to those induced by AT. These observations strongly suggest that AT reduces the I/R-induced renal injury by inhibiting leukocyte activation. The therapeutic effects of AT might be mainly mediated by PGI(2) released from endothelial cells through interaction of AT with cell surface glycosaminoglycans.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
101
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3029-36
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12480701-6-Ketoprostaglandin F1 alpha, pubmed-meshheading:12480701-Amino Acid Chloromethyl Ketones, pubmed-meshheading:12480701-Animals, pubmed-meshheading:12480701-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:12480701-Antithrombin III, pubmed-meshheading:12480701-Capillary Permeability, pubmed-meshheading:12480701-Drug Evaluation, Preclinical, pubmed-meshheading:12480701-Endothelium, Vascular, pubmed-meshheading:12480701-Epoprostenol, pubmed-meshheading:12480701-Factor Xa, pubmed-meshheading:12480701-Iloprost, pubmed-meshheading:12480701-Indomethacin, pubmed-meshheading:12480701-Ischemia, pubmed-meshheading:12480701-Kidney, pubmed-meshheading:12480701-Lymphocyte Activation, pubmed-meshheading:12480701-Male, pubmed-meshheading:12480701-Peroxidase, pubmed-meshheading:12480701-Rats, pubmed-meshheading:12480701-Rats, Wistar, pubmed-meshheading:12480701-Reperfusion Injury, pubmed-meshheading:12480701-Specific Pathogen-Free Organisms, pubmed-meshheading:12480701-Tumor Necrosis Factor-alpha
pubmed:year
2003
pubmed:articleTitle
Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production.
pubmed:affiliation
Intensive Care Unit, Oita Medical University, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't